PAVM - PAVmed lags consensus with early revenue estimates for Q3

PAVmed (NASDAQ:PAVM) shares have lost ~6.7% in the post-market after the company disclosed preliminary financial results for the third quarter of 2021 that fell short of Street forecasts. The company has recorded $0.20M in revenue for the quarter, while the consensus revenue estimates stood at $0.28M. Meanwhile, the net loss attributable to common stockholders reached ~$12.3M or $(0.15) per share and $8.2M or $(0.10) per share on a GAAP basis and adj. basis, respectively. The consensus estimates for the company indicate $(0.13) in EPS. PAVmed (PAVM) has raised its stake in the subsidiary Lucid Diagnostics (NASDAQ:LUCD) from ~73% to ~76% with the conversion of $22.4M of promissory notes and purchase of $0.6M worth shares at the public offering in October. Read: Lucid Diagnostics (LUCD) fell sharply on its public debut.

For further details see:

PAVmed lags consensus with early revenue estimates for Q3